- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00234442
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
June 29, 2009 updated by: AstraZeneca
A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
47
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bologna, Italy
- Research Site
-
Orbassano, Italy
- Research Site
-
Parma, Italy
- Research Site
-
Rozzano, Italy
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Radiologically confirmed brain metastases from Non Small Cell Lung Cancer
- No symptoms due to brain metastases
- No previous radiotherapy treatment for the Brain metastases
Exclusion Criteria:
- No prior chemotherapy
- No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
- Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Disease control rate (complete response, partial response and stable disease)
|
Secondary Outcome Measures
Outcome Measure |
---|
Time to progression
|
Duration of response
|
Overall Survival
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lucio Crino, MD, Bologna, Italy
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2004
Study Completion
February 1, 2006
Study Registration Dates
First Submitted
October 5, 2005
First Submitted That Met QC Criteria
October 5, 2005
First Posted (Estimate)
October 7, 2005
Study Record Updates
Last Update Posted (Estimate)
June 30, 2009
Last Update Submitted That Met QC Criteria
June 29, 2009
Last Verified
June 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- Brain Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Gefitinib
Other Study ID Numbers
- 1839IL/0569
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Neoplasms
-
Constantinos HadjipanayisNational Cancer Institute (NCI); NX PharmaGenWithdrawnGlioblastoma | Brain Cancer | Brain Tumors | Brain Tumor, Recurrent | Benign Neoplasms, Brain | Brain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Tumor, Primary | Intracranial Neoplasms | Neoplasms, Brain | Neoplasms, Intracranial | Primary Brain Neoplasms | Primary Malignant Brain Neoplasms | Primary Malignant... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedBrain Cancer | Brain Neoplasm | Brain Tumor, PrimaryUnited States
-
Vanderbilt University Medical CenterUniversity of Alabama at Birmingham; Emory University; H. Lee Moffitt Cancer... and other collaboratorsTerminatedBrain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Neoplasm, PrimaryUnited States
-
BioNumerik Pharmaceuticals, Inc.Crown BioscienceCompletedBrain Neoplasms | Brain Tumors | Malignant Neoplasms, BrainUnited States
-
National Cancer Institute (NCI)TerminatedCentral Nervous System Neoplasms | Brain Cancer | Neoplasms, Brain | Primary Brain Neoplasms | Cancer of the BrainUnited States
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Lawson Health Research InstituteCompletedBrain Tumor | Brain Neoplasm | Tumor, Brain | Neoplasm, Supratentorial | Tumor, SupratentorialCanada
-
Tomsk National Research Medical Center of the Russian...Uppsala UniversityCompletedNeoplasms | BrainRussian Federation
Clinical Trials on Iressa (Gefitinib)
-
AstraZenecaCompletedNeoplasms, Squamous CellUnited States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
-
Sun Yat-sen UniversityWu Jieping Medical FoundationCompletedNon-small Cell Lung CancerChina
-
University Health Network, TorontoAstraZenecaCompleted
-
Tianjin Medical University Cancer Institute and...SuspendedNon Small Cell Lung CancerChina
-
AstraZenecaTerminatedNon Small Cell Lung CarcinomaItaly
-
AstraZenecaApproved for marketingNon Small Cell Lung Cancer (NSCLC)Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
-
Hunan Kelun Pharmaceutical Co., Ltd.CompletedBioequivalence Study
-
AstraZenecaCompleted
-
Chonnam National University HospitalAstraZenecaCompletedCarcinoma, Non-Small-Cell LungKorea, Republic of